Journal Club
1. Spectrum Of Pulmonary Fungal Pathogens And Antifungal Drug Susceptibility Among TB Relapse And Retreatment Samples At Selected Health Facilities In Kenya - PhD Research Update
0
IAVI-W001 Study Launched at the KAVI-Institute of Clinical Research
On 24th September 2019, the first volunteer was enrolled in the IAVI-W001 study at the KAVI-Institute of Clinical Research (KAVI-ICR) of the University of Nairobi. The occasion marks the beginning of the 12th HIV vaccine clinical trial to be conducted at KAVI-ICR since 2001. This is a first-in-human study that uses a Native-trimer HIV envelope design that will hopefully stimulate broadly neutralizing antibodies against HIV.
0
New Phase 2 Cholera Vaccine Trial Launches in Nairobi
Nairobi, Kenya — The International Vaccine Institute (IVI), in partnership with the KAVI–Institute of Clinical Research (KAVI-ICR) at the University of Nairobi, has officially launched a Phase 2 clinical trial of a novel cholera conjugate vaccine. This study is now actively recruiting adults and children from Nairobi City County to take part in what could be a significant advance in cholera prevention.